Key result
Histologic response to neoadjuvant chemotherapy did not correlate with overall or event-free survival in patients with extremity soft tissue sarcoma.
Why the study?
Does histologic response to neoadjuvant chemotherapy predict overall or event-free survival in patients with high-grade extremity soft tissue sarcoma?
Cohort (n=31)
No
Does histologic response to neoadjuvant chemotherapy predict overall or event-free survival in patients with high-grade extremity soft tissue sarcoma?
Histologic response to neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma does not reliably predict overall or event-free survival.
Answers are grounded in this paper and cite their sources.
Histologic response should not guide prognosis or neoadjuvant decisions in extremity STS; challenges its validity as a surrogate endpoint.
Learning Objectives After completing this course, the reader will be able to: Use the correlation of all data from clinical, imaging, and histopathologic observations by a multidisciplinary tumor board in the prognosis of patients with soft tissue sarcoma.Interpret the prognostic value of histologic response to chemotherapy in soft tissue sarcoma in contrast to its value in osteosarcoma and Ewing's sarcoma.Evaluate the profound histologic alterations induced by neoadjuvant chemotherapy in soft tissue sarcomas. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com Histologic response to chemotherapy is generally regarded as an independent prognostic variable in bone sarcomas, both osteosarcoma and Ewing's sarcoma. In soft tissue sarcomas, however, descriptions of histologic alterations from chemotherapy and correlative outcome studies are much more limited. Herein we report clinicopathological findings from a homogeneously treated group of 31 patients with tumor stage T2 grade 3 extremity soft tissue sarcomas treated with the same neoadjuvant chemotherapy followed by surgical excision, treated by the same medical oncologist and orthopedic surgeon. Histologic response to therapy was evaluated by multiple parameters using a semiquantitative grading system. Based upon the percentage of post-treatment viable tumor, tumors were arbitrarily categorized similarly to Huvos score as showing excellent (≤5% viability), moderate (6%–49% viability), or poor (≥50% viability) responses. Nineteen percent had excellent, 10% had moderate, and 71% had poor responses. These histologic response groups did not correlate with overall or event-free survival. For example, of the 22 patients showing a “poor” response, 13 were cured. Similarly, other histologic parameters, including percentages of necrosis, fibrosis/hyalinization, and cellular degeneration, did not correlate with outcome. Chemotherapy induces profound tissue alterations in soft tissue sarcomas. However, histologic alteration by itself may not be a reliable prognostic variable. Correlation of all data from clinical, imaging, and pathological observations by a multidisciplinary tumor board should have greater prognostic value than histology alone. Finally, although the histologic grading system used in this study could not be validated, the criteria we employed are simple and reproducible and take into account the major histologic patterns seen after therapy, and would be amenable for use in future studies.
No takes yet. Share an insight, caveat, or question.
Lucas et al. (2008) conducted a cohort in Tumor stage T2 grade 3 extremity soft tissue sarcomas (n=31). Histologic response to neoadjuvant chemotherapy was evaluated on Overall or event-free survival. Histologic response to neoadjuvant chemotherapy did not correlate with overall or event-free survival in patients with extremity soft tissue sarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: